Eris Lifesciences (ERIS) Stock Overview
Provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
ERIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eris Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,575.70 |
| 52 Week High | ₹1,910.00 |
| 52 Week Low | ₹1,097.20 |
| Beta | -0.090 |
| 1 Month Change | -1.30% |
| 3 Month Change | -10.25% |
| 1 Year Change | 15.14% |
| 3 Year Change | 134.44% |
| 5 Year Change | 202.23% |
| Change since IPO | 161.96% |
Recent News & Updates
Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Nov 15
Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?
Aug 28Recent updates
Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Nov 15Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value?
Aug 28Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Jul 26Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26%
Jun 17Eris Lifesciences' (NSE:ERIS) Conservative Accounting Might Explain Soft Earnings
May 26Earnings Miss: Eris Lifesciences Limited Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
May 23Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
Apr 28
Semaglutide Launch Will Secure Early Position In India's GLP-1 Market
Strategic GLP-1 market entry and Bhopal facility ramp-up are expected to boost revenue and margins through innovation and operational efficiency.These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Reasonably Well
Mar 03Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results
Feb 09What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E
Jan 07Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Shareholder Returns
| ERIS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.3% | 1.6% | 1.3% |
| 1Y | 15.1% | 1.1% | 6.2% |
Return vs Industry: ERIS exceeded the Indian Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: ERIS exceeded the Indian Market which returned 6.2% over the past year.
Price Volatility
| ERIS volatility | |
|---|---|
| ERIS Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: ERIS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ERIS's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3,354 | Amit Bakshi | www.eris.co.in |
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions.
Eris Lifesciences Limited Fundamentals Summary
| ERIS fundamental statistics | |
|---|---|
| Market cap | ₹213.37b |
| Earnings (TTM) | ₹4.15b |
| Revenue (TTM) | ₹29.86b |
Is ERIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERIS income statement (TTM) | |
|---|---|
| Revenue | ₹29.86b |
| Cost of Revenue | ₹7.53b |
| Gross Profit | ₹22.33b |
| Other Expenses | ₹18.18b |
| Earnings | ₹4.15b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 30.47 |
| Gross Margin | 74.77% |
| Net Profit Margin | 13.90% |
| Debt/Equity Ratio | 66.6% |
How did ERIS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 11:20 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eris Lifesciences Limited is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Pranav Chawla | Ambit Capital |